Literature DB >> 25775353

Age, Sex, and APOE ε4 Effects on Memory, Brain Structure, and β-Amyloid Across the Adult Life Span.

Clifford R Jack1, Heather J Wiste2, Stephen D Weigand2, David S Knopman3, Prashanthi Vemuri1, Michelle M Mielke2, Val Lowe1, Matthew L Senjem1, Jeffrey L Gunter1, Mary M Machulda4, Brian E Gregg1, V Shane Pankratz2, Walter A Rocca5, Ronald C Petersen3.   

Abstract

IMPORTANCE: Typical cognitive aging may be defined as age-associated changes in cognitive performance in individuals who remain free of dementia. Ideally, the full adult age spectrum should be included to assess brain imaging findings associated with typical aging.
OBJECTIVE: To compare age, sex, and APOE ε4 effects on memory, brain structure (adjusted hippocampal volume [HVa]), and amyloid positron emission tomography (PET) in cognitively normal individuals aged 30 to 95 years old. DESIGN, SETTING, AND PARTICIPANTS: Cross-sectional observational study (March 2006 to October 2014) at an academic medical center. We studied 1246 cognitively normal individuals, including 1209 participants aged 50 to 95 years old enrolled in a population-based study of cognitive aging and 37 self-selected volunteers aged 30 to 49 years old. MAIN OUTCOMES AND MEASURES: Memory, HVa, and amyloid PET.
RESULTS: Overall, memory worsened from age 30 years through the 90s. The HVa worsened gradually from age 30 years to the mid-60s and more steeply beyond that age. The median amyloid PET was low until age 70 years and increased thereafter. Memory was worse in men than in women overall (P < .001) and more specifically beyond age 40 years. The HVa was lower in men than in women overall (P < .001) and more specifically beyond age 60 years. There was no sex difference in amyloid PET at any age. Within each sex, memory performance and HVa were not different by APOE ε4 status at any age. From age 70 years onward, APOE ε4 carriers had significantly greater median amyloid PET than noncarriers. However, the ages at which 10% of the population were amyloid PET positive were 57 years for APOE ε4 carriers and 64 years for noncarriers. CONCLUSIONS AND RELEVANCE: Male sex is associated with worse memory and HVa among cognitively normal individuals, while APOE ε4 is not. In contrast, APOE ε4 is associated with greater amyloid PET (from age 70 years onward), while sex is not. Worsening memory and HVa occur at earlier ages than abnormal amyloid PET. Therefore, neuropathological processes other than β-amyloidosis must underlie declines in brain structure and memory function in middle age. Our findings are consistent with a model of late-onset Alzheimer disease in which β-amyloidosis arises in later life on a background of preexisting structural and cognitive decline that is associated with aging and not with β-amyloid deposits.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25775353      PMCID: PMC4428984          DOI: 10.1001/jamaneurol.2014.4821

Source DB:  PubMed          Journal:  JAMA Neurol        ISSN: 2168-6149            Impact factor:   18.302


  59 in total

1.  The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET.

Authors:  William E Klunk; Robert A Koeppe; Julie C Price; Tammie L Benzinger; Michael D Devous; William J Jagust; Keith A Johnson; Chester A Mathis; Davneet Minhas; Michael J Pontecorvo; Christopher C Rowe; Daniel M Skovronsky; Mark A Mintun
Journal:  Alzheimers Dement       Date:  2014-10-28       Impact factor: 21.566

2.  APOE4 allele disrupts resting state fMRI connectivity in the absence of amyloid plaques or decreased CSF Aβ42.

Authors:  Yvette I Sheline; John C Morris; Abraham Z Snyder; Joseph L Price; Zhizi Yan; Gina D'Angelo; Collin Liu; Sachin Dixit; Tammie Benzinger; Anne Fagan; Alison Goate; Mark A Mintun
Journal:  J Neurosci       Date:  2010-12-15       Impact factor: 6.167

3.  Longitudinal modeling of age-related memory decline and the APOE epsilon4 effect.

Authors:  Richard J Caselli; Amylou C Dueck; David Osborne; Marwan N Sabbagh; Donald J Connor; Geoffrey L Ahern; Leslie C Baxter; Steven Z Rapcsak; Jiong Shi; Bryan K Woodruff; Dona E C Locke; Charlene Hoffman Snyder; Gene E Alexander; Rosa Rademakers; Eric M Reiman
Journal:  N Engl J Med       Date:  2009-07-16       Impact factor: 91.245

4.  Alzheimer's disease neurodegenerative biomarkers are associated with decreased cognitive function but not β-amyloid in cognitively normal older individuals.

Authors:  Miranka Wirth; Cindee M Madison; Gil D Rabinovici; Hwamee Oh; Susan M Landau; William J Jagust
Journal:  J Neurosci       Date:  2013-03-27       Impact factor: 6.167

5.  Cross-sectional and longitudinal analysis of the relationship between Aβ deposition, cortical thickness, and memory in cognitively unimpaired individuals and in Alzheimer disease.

Authors:  Vincent Doré; Victor L Villemagne; Pierrick Bourgeat; Jurgen Fripp; Oscar Acosta; Gael Chetélat; Luping Zhou; Ralph Martins; Kathryn A Ellis; Colin L Masters; David Ames; Oliver Salvado; Christopher C Rowe
Journal:  JAMA Neurol       Date:  2013-07       Impact factor: 18.302

6.  Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study.

Authors:  Victor L Villemagne; Samantha Burnham; Pierrick Bourgeat; Belinda Brown; Kathryn A Ellis; Olivier Salvado; Cassandra Szoeke; S Lance Macaulay; Ralph Martins; Paul Maruff; David Ames; Christopher C Rowe; Colin L Masters
Journal:  Lancet Neurol       Date:  2013-03-08       Impact factor: 44.182

7.  Cognitive aging in persons with minimal amyloid-β and white matter hyperintensities.

Authors:  Robert D Nebes; Beth E Snitz; Ann D Cohen; Howard J Aizenstein; Judith A Saxton; Edythe M Halligan; Chester A Mathis; Julie C Price; M Ilyas Kamboh; Lisa A Weissfeld; William E Klunk
Journal:  Neuropsychologia       Date:  2013-08-01       Impact factor: 3.139

8.  Age-specific population frequencies of cerebral β-amyloidosis and neurodegeneration among people with normal cognitive function aged 50-89 years: a cross-sectional study.

Authors:  Clifford R Jack; Heather J Wiste; Stephen D Weigand; Walter A Rocca; David S Knopman; Michelle M Mielke; Val J Lowe; Matthew L Senjem; Jeffrey L Gunter; Gregory M Preboske; Vernon S Pankratz; Prashanthi Vemuri; Ronald C Petersen
Journal:  Lancet Neurol       Date:  2014-09-04       Impact factor: 44.182

Review 9.  Apolipoprotein E as a β-amyloid-independent factor in Alzheimer's disease.

Authors:  Andrew B Wolf; Jon Valla; Guojun Bu; Jungsu Kim; Mary Jo LaDu; Eric M Reiman; Richard J Caselli
Journal:  Alzheimers Res Ther       Date:  2013-09-03       Impact factor: 6.982

10.  Rates of β-amyloid accumulation are independent of hippocampal neurodegeneration.

Authors:  Clifford R Jack; Heather J Wiste; David S Knopman; Prashanthi Vemuri; Michelle M Mielke; Stephen D Weigand; Matthew L Senjem; Jeffrey L Gunter; Val Lowe; Brian E Gregg; Vernon S Pankratz; Ronald C Petersen
Journal:  Neurology       Date:  2014-04-04       Impact factor: 9.910

View more
  154 in total

1.  Alzheimer's disease cerebrospinal fluid biomarker in cognitively normal subjects.

Authors:  Jon B Toledo; Henrik Zetterberg; Argonde C van Harten; Lidia Glodzik; Pablo Martinez-Lage; Luisella Bocchio-Chiavetto; Lorena Rami; Oskar Hansson; Reisa Sperling; Sebastiaan Engelborghs; Ricardo S Osorio; Hugo Vanderstichele; Manu Vandijck; Harald Hampel; Stefan Teipl; Abhay Moghekar; Marilyn Albert; William T Hu; Jose A Monge Argilés; Ana Gorostidi; Charlotte E Teunissen; Peter P De Deyn; Bradley T Hyman; Jose L Molinuevo; Giovanni B Frisoni; Gurutz Linazasoro; Mony J de Leon; Wiesje M van der Flier; Philip Scheltens; Kaj Blennow; Leslie M Shaw; John Q Trojanowski
Journal:  Brain       Date:  2015-07-27       Impact factor: 13.501

2.  Inverse effect of the APOE epsilon4 allele in late- and early-onset Alzheimer's disease.

Authors:  Vincenzo De Luca; Maria Donata Orfei; Sara Gaudenzi; Carlo Caltagirone; Gianfranco Spalletta
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2015-12-29       Impact factor: 5.270

3.  Influence of apolipoprotein-E genotype on brain amyloid load and longitudinal trajectories.

Authors:  Brian J Lopresti; Elizabeth M Campbell; Zheming Yu; Stewart J Anderson; Ann D Cohen; Davneet S Minhas; Beth E Snitz; Sarah K Royse; Carl R Becker; Howard J Aizenstein; Chester A Mathis; Oscar L Lopez; William E Klunk; Dana L Tudorascu
Journal:  Neurobiol Aging       Date:  2020-05-31       Impact factor: 4.673

4.  Cytochrome P450 27A1 Deficiency and Regional Differences in Brain Sterol Metabolism Cause Preferential Cholestanol Accumulation in the Cerebellum.

Authors:  Natalia Mast; Kyle W Anderson; Joseph B Lin; Yong Li; Illarion V Turko; Curtis Tatsuoka; Ingemar Bjorkhem; Irina A Pikuleva
Journal:  J Biol Chem       Date:  2017-02-11       Impact factor: 5.157

Review 5.  Association between Various Brain Pathologies and Gait Disturbance.

Authors:  Alexandra M V Wennberg; Rodolfo Savica; Michelle M Mielke
Journal:  Dement Geriatr Cogn Disord       Date:  2017-02-03       Impact factor: 2.959

6.  Multimorbidity and neuroimaging biomarkers among cognitively normal persons.

Authors:  Maria Vassilaki; Jeremiah A Aakre; Michelle M Mielke; Yonas E Geda; Walter K Kremers; Rabe E Alhurani; Mary M Machulda; David S Knopman; Ronald C Petersen; Val J Lowe; Clifford R Jack; Rosebud O Roberts
Journal:  Neurology       Date:  2016-04-13       Impact factor: 9.910

7.  Sex, amyloid, and APOE ε4 and risk of cognitive decline in preclinical Alzheimer's disease: Findings from three well-characterized cohorts.

Authors:  Rachel F Buckley; Elizabeth C Mormino; Rebecca E Amariglio; Michael J Properzi; Jennifer S Rabin; Yen Ying Lim; Kathryn V Papp; Heidi I L Jacobs; Samantha Burnham; Bernard J Hanseeuw; Vincent Doré; Annette Dobson; Colin L Masters; Michael Waller; Christopher C Rowe; Paul Maruff; Michael C Donohue; Dorene M Rentz; Dylan Kirn; Trey Hedden; Jasmeer Chhatwal; Aaron P Schultz; Keith A Johnson; Victor L Villemagne; Reisa A Sperling
Journal:  Alzheimers Dement       Date:  2018-05-24       Impact factor: 21.566

8.  Brain atrophy in primary age-related tauopathy is linked to transactive response DNA-binding protein of 43 kDa.

Authors:  Keith A Josephs; Melissa E Murray; Nirubol Tosakulwong; Stephen D Weigand; David S Knopman; Ronald C Petersen; Clifford R Jack; Jennifer L Whitwell; Dennis W Dickson
Journal:  Alzheimers Dement       Date:  2019-05-02       Impact factor: 21.566

9.  Impact of Alzheimer's Disease, Lewy Body and Vascular Co-Pathologies on Clinical Transition to Dementia in a National Autopsy Cohort.

Authors:  Jagan A Pillai; Robert S Butler; Aaron Bonner-Jackson; James B Leverenz
Journal:  Dement Geriatr Cogn Disord       Date:  2016-09-14       Impact factor: 2.959

10.  Evolution of neurodegeneration-imaging biomarkers from clinically normal to dementia in the Alzheimer disease spectrum.

Authors:  David S Knopman; Clifford R Jack; Emily S Lundt; Stephen D Weigand; Prashanthi Vemuri; Val J Lowe; Kejal Kantarci; Jeffrey L Gunter; Matthew L Senjem; Michelle M Mielke; Mary M Machulda; Rosebud O Roberts; Bradley F Boeve; David T Jones; Ronald C Petersen
Journal:  Neurobiol Aging       Date:  2016-06-16       Impact factor: 4.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.